Xifaxan ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1
94	Primary sclerosing cholangitis	1

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-000883-27-NO (EUCTR)	16/08/2013	20/06/2013	The effects of the local acting antibiotic Rifaximin on markers of inflammation in the blood by changing the bacterial composition in the gut, in patients with common variable immunodeficiency.	EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL	Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Xifaxan	Oslo University hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Norway

Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01695174 (ClinicalTrials.gov)	August 2012	25/9/2012	A Pilot Study of Xifaxan to Treat Patients With PSC	A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis (PSC)	Drug: Xifaxan	Mayo Clinic	NULL	Completed	18 Years	75 Years	Both	16	Phase 1	United States